180 related articles for article (PubMed ID: 22247653)
1. Serological thymidine kinase 1 is a biomarker for early detection of tumours--a health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay.
Chen ZH; Huang SQ; Wang Y; Yang AZ; Wen J; Xu XH; Chen Y; Chen QB; Wang YH; He E; Zhou J; Skog S
Sensors (Basel); 2011; 11(12):11064-80. PubMed ID: 22247653
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum thymidine kinase 1 predicts risk of pre/early cancerous progression.
Huang S; Lin J; Guo N; Zhang M; Yun X; Liu S; Zhou J; He E; Skog S
Asian Pac J Cancer Prev; 2011; 12(2):497-505. PubMed ID: 21545220
[TBL] [Abstract][Full Text] [Related]
3. Serological thymidine kinase 1 (STK1) indicates an elevated risk for the development of malignant tumours.
Chen Z; Zhou H; Li S; He E; Hu J; Zhou J; Skog S
Anticancer Res; 2008; 28(6B):3897-907. PubMed ID: 19192647
[TBL] [Abstract][Full Text] [Related]
4. [Application of serum thymidine kinase 1 of 26 055 cases in health screening for early detection of premalignant/early malignant tumors].
Cao X; Wang Y; Yang P; Zhou H; Liu C; Chen Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Oct; 39(10):1029-34. PubMed ID: 25355255
[TBL] [Abstract][Full Text] [Related]
5. Serum TK1 is a more reliable marker than CEA and AFP for cancer screening in a study of 56,286 people.
Wang Y; Jiang X; Dong S; Shen J; Yu H; Zhou J; Li J; Ma H; He E; Skog S
Cancer Biomark; 2016 Mar; 16(4):529-36. PubMed ID: 27002755
[TBL] [Abstract][Full Text] [Related]
6. Serological TK1 predict pre-cancer in routine health screenings of 56,178 people.
Wang Y; Jiang X; Wang S; Yu H; Zhang T; Xu S; Li W; He E; Skog S
Cancer Biomark; 2018; 22(2):237-247. PubMed ID: 29689706
[TBL] [Abstract][Full Text] [Related]
7. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings.
Chen Y; Ying M; Chen Y; Hu M; Lin Y; Chen D; Li X; Zhang M; Yun X; Zhou J; He E; Skog S
Int J Clin Oncol; 2010 Aug; 15(4):359-68. PubMed ID: 20354751
[TBL] [Abstract][Full Text] [Related]
8. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer.
Li HX; Lei DS; Wang XQ; Skog S; He Q
Oncol Rep; 2005 Jan; 13(1):145-9. PubMed ID: 15583816
[TBL] [Abstract][Full Text] [Related]
9. Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker.
Jagarlamudi KK; Hansson LO; Eriksson S
BMC Cancer; 2015 Feb; 15():66. PubMed ID: 25881026
[TBL] [Abstract][Full Text] [Related]
10. The half-life of thymidine kinase 1 in serum measured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer.
Zou L; Zhang PG; Zou S; Li Y; He Q
Int J Biol Markers; 2002; 17(2):135-40. PubMed ID: 12113581
[TBL] [Abstract][Full Text] [Related]
11. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients.
Zhang J; Jia Q; Zou S; Zhang P; Zhang X; Skog S; Luo P; Zhang W; He Q
Oncol Rep; 2006 Feb; 15(2):455-61. PubMed ID: 16391869
[TBL] [Abstract][Full Text] [Related]
12. Properties of cellular and serum forms of thymidine kinase 1 (TK1) in dogs with acute lymphocytic leukemia (ALL) and canine mammary tumors (CMTs): implications for TK1 as a proliferation biomarker.
Jagarlamudi KK; Westberg S; Rönnberg H; Eriksson S
BMC Vet Res; 2014 Oct; 10():228. PubMed ID: 25293656
[TBL] [Abstract][Full Text] [Related]
13. Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas.
Li Z; Wang Y; He J; Ma J; Zhao L; Chen H; Li N; Zhou J; He E; Skog S
Eur J Cancer Prev; 2010 Jul; 19(4):313-8. PubMed ID: 20479645
[TBL] [Abstract][Full Text] [Related]
14. Serum thymidine kinase 1 reflects the progression of pre-malignant and malignant tumors during therapy.
Xu XH; Zhang YM; Shu XH; Shan LH; Wang ZW; Zhou YL; Wen HK; He F; He E; Skog S
Mol Med Rep; 2008; 1(5):705-11. PubMed ID: 21479474
[TBL] [Abstract][Full Text] [Related]
15. Transient increase in serum thymidine kinase 1 within one week after surgery of patients with carcinoma.
Li Z; Wang Y; Ma J; He J; Zhou J; He E; Skog S
Anticancer Res; 2010 Apr; 30(4):1295-9. PubMed ID: 20530443
[TBL] [Abstract][Full Text] [Related]
16. High levels of inactive thymidine kinase 1 polypeptide detected in sera from dogs with solid tumours by immunoaffinity methods: implications for in vitro diagnostics.
Kiran Kumar J; Sharif H; Westberg S; von Euler H; Eriksson S
Vet J; 2013 Sep; 197(3):854-60. PubMed ID: 23831216
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of serum thymidine kinase 1 activity as a biomarker for treatment effectiveness and prediction of relapse in dogs with non-Hodgkin lymphoma.
Boyé P; Floch F; Serres F; Geeraert K; Clerson P; Siomboing X; Bergqvist M; Sack G; Tierny D
J Vet Intern Med; 2019 Jul; 33(4):1728-1739. PubMed ID: 31129922
[TBL] [Abstract][Full Text] [Related]
18. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients.
Pan ZL; Ji XY; Shi YM; Zhou J; He E; Skog S
J Cancer Res Clin Oncol; 2010 Aug; 136(8):1193-9. PubMed ID: 20140744
[TBL] [Abstract][Full Text] [Related]
19. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity.
He Q; Zhang P; Zou L; Li H; Wang X; Zhou S; Fornander T; Skog S
Oncol Rep; 2005 Oct; 14(4):1013-9. PubMed ID: 16142366
[TBL] [Abstract][Full Text] [Related]
20. Standardized Centile Curves and Reference Intervals of Serum Thymidine Kinase 1 Levels in a Normal Chinese Population Using the LMS Method.
Cao X; Zhou J; Chen Z
Genet Test Mol Biomarkers; 2016 Aug; 20(8):445-50. PubMed ID: 27337028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
